World's Best Scientists 2026 revealed!
Stephen M. Ansell

Stephen M. Ansell

D-Index & Metrics

Medicine

D-Index
120
Citations
55337
World Ranking
3740
National Ranking
2059

Overview

Stephen M. Ansell is affiliated with the Mayo Clinic in the United States. Their research primarily focuses on medicine, with significant contributions spanning pathology and forensic medicine, oncology, genetics, immunology, and neurology.

The scientist's main topics of work include lymphoma diagnosis and treatment, CAR-T cell therapy research, chronic lymphocytic leukemia research, cancer immunotherapy and biomarkers, immune cell function and interaction, CNS lymphoma diagnosis and treatment, and viral-associated cancers and disorders.

Frequent publication venues for their work are prominent journals such as Blood, Journal of Clinical Oncology, Clinical Lymphoma Myeloma & Leukemia, Blood Cancer Journal, and Hematological Oncology.

Stephen M. Ansell has collaborated regularly with several coauthors, including Jonas Paludo, José C. Villasboas, Thomas M. Habermann, Patrick B. Johnston, and Yucai Wang.

Notable recent papers include:

  • The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee, 2022, Blood
  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma, 2022, New England Journal of Medicine
  • Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results, 2021, Blood
  • Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies, 2021, Clinical Cancer Research
  • Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial, 2021, The Lancet Haematology

Best Publications

  • PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    Stephen M. Ansell;Alexander M. Lesokhin;Alexander M. Lesokhin;Ivan Borrello;Ahmad Halwani

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

    Jens G. Lohr;Petar Stojanov;Petar Stojanov;Michael S. Lawrence;Daniel Auclair

  • Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study

    Alexander M. Lesokhin;Alexander M. Lesokhin;Stephen M. Ansell;Philippe Armand;Emma C. Scott

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

    Yucai Wang;Shouhao Zhou;Shouhao Zhou;Fang Yang;Xinyue Qi

  • Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

    Thomas E. Witzig;Susan M. Geyer;Irene Ghobrial;David J. Inwards

  • Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma

    Zhi Zhang Yang;Anne J. Novak;Mary J. Stenson;Thomas E. Witzig

  • ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

    Edgardo R. Parrilla Castellar;Elaine S. Jaffe;Jonathan W. Said;Steven H. Swerdlow

  • An APRIL to remember: novel TNF ligands as therapeutic targets

    Stacey R. Dillon;Jane A. Gross;Stephen M. Ansell;Anne J. Novak

  • Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

    Bruce D. Cheson;Stephen Ansell;Larry Schwartz;Leo I. Gordon

  • Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

    Wei Ding;Betsy R. LaPlant;Timothy G. Call;Sameer A. Parikh

  • Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

    Stephen M. Ansell;Sara A. Hurvitz;Patricia A. Koenig;Betsy R. LaPlant

  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Robert Chen;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

    Angela Dispenzieri;Morie A. Gertz;Robert A. Kyle;Martha Q. Lacy

  • Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

    Luis F. Porrata;Morie A. Gertz;David J. Inwards;Mark R. Litzow

  • Non-Hodgkin lymphoma: diagnosis and treatment.

    Stephen M. Ansell;James Olen Armitage

  • Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

    Grzegorz S Nowakowski;Betsy LaPlant;William R Macon;Craig B Reeder

  • Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma

    Frank A. Sinicrope;Rafaela L. Rego;Stephen M. Ansell;Keith L. Knutson

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always require following the traditional path of medical school. There are numerous related online degree programs and career pathways worth considering, each offering unique opportunities and benefits.

If you enjoy working with healthcare data and administration, consider looking into medical billing and coding financial aid options. These accredited online programs can help reduce costs and make it easier to start your career in health information management.

Nursing is another rewarding field, and not all programs have strict entrance requirements. Are you wondering, do you have to take the teas test to get into nursing school? Some schools may waive this requirement, providing more flexible entry points into nursing careers.

For those interested in leadership roles, a health administration degree can be pursued online, often in an accelerated format. This opens the door to management roles in hospitals, clinics, and other healthcare organizations.

If you’re already a registered nurse, advancing your education through one of the top rn to fnp bridge programs can help you become a Family Nurse Practitioner (FNP), expanding your scope of practice and career opportunities.

Best Scientists Citing Stephen M. Ansell

Trending Scientists